Melinda Gooderham

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

Medicine, Dermatology, Immunology +17

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine · 2017 · 511 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried et al. · JAMA Dermatology · 2019 · 509 citations · Full text

Medicine, Dermatology, Immunology +13

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

C. Paul, Jennifer Clay Cather, Melinda Gooderham et al. · British Journal of Dermatology · 2015 · 479 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial

Robert Bissonnette, Kim Papp, Yves Poulin et al. · British Journal of Dermatology · 2016 · 418 citations · Full text

Life Sciences, Dermatology, Pharmacology +15